Investors & Operators Ep. 108 Unlocking Stem Cell Potential with Ruby Tsai, CEO and Co-founder at Applied StemCell
Mar 21, 2024
42:15
It currently costs up to $500,000 per dose for stem cell therapy. Applied StemCell is going to change that.
In this episode of Investors & Operators, Jordan speaks with Ruby Tsai, CEO and Co-founder at Applied StemCell, for a fascinating discussion on stem cells and how her partnership with a private equity firm - QHP - is taking ASC to the next level. Together, they discuss:
- How ASC is revolutionizing gene editing
- Current Cell Therapies
- Partnering with QHP
...and so much more.
Top Takeaways
- Always believe in your business. Ruby firmly believes in Applied StemCell, which led her to leave her position at Stanford University. Her faith in ASC’s potential impact and ability to save human lives truly drove her decision. While initially scared to make the jump, Ruby emphasizes the importance of believing in yourself and your businesses, sticking to your values, and having faith in your work. Highlighting the importance of pursuing what you believe in and what aligns with your values.
- The importance of the management system. When discussing QHP’s management system, a framework that transforms companies that are at a growth inflection point, Ruby notes "I didn't pay that much attention to it." She shares how she initially overlooked the management system, but after a week of installation training and hands-on experience, she truly understood its significance. Proper implementation of this system leads to increased productivity and effectiveness throughout a team and organization, particularly for companies at a growth inflection point. Rather than getting caught up in day-to-day operational tasks, Ruby emphasizes the importance of focusing on company strategy through the management framework.